John Holaday, CEO, QrX Pharma. A New Pain Management Paradigm




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: John Holaday, CEO, QrX Pharma. A New Pain Management Paradigm
Released on: March 31, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this interview filmed at AusBiotech 2013 Fintan Walton speaks with John Holaday, CEO, QrX Pharma
  • Summary
  • Transcript
  • Participants
  • Company
In this interview filmed at AusBiotech 2013 Fintan Walton speaks with John Holaday, CEO, QrX Pharma
In this interview filmed at AusBiotech 2013 Fintan Walton speaks with John Holaday, CEO, QrX Pharma
John Holaday
QrX Pharma
QRX Pharma Ltd
QRxPharma (ASX: QRX and OTCQX: QRXPY) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of therapies for pain management and central nervous system (CNS) disorders. Based on a business strategy to expand the clinical utility and commercial value of marketed and/or existing compounds, QRxPharma’s product portfolio includes both late and early stage clinical drug candidates with well-defined paths to regulatory approval and sales. The Company intends to directly commercialise its products in the US and seek strategic partnerships for worldwide markets.